BIFIDOBACTERIA STRAIN

专利摘要:
strain of bifidobacteria. the strain of bifidobacterium ah121a is significantly immunomodulatory after oral consumption. the strain is useful as an immunomodulatory biotherapy agent.
公开号:BR112012010923B1
申请号:R112012010923-5
申请日:2010-11-11
公开日:2021-03-23
发明作者:Liam O'Mahony；Barry Kiely
申请人:Alimentary Health Limited；Mars, Incorporated；
IPC主号:

专利说明:

[0001] The present invention relates to a bifidobacterial strain and its use as a probiotic bacterium, particularly as an immunomodulatory biotherapeutic agent.
[0002] The defense mechanisms for the protection of the human gastrointestinal tract from colonization by intestinal bacteria are highly complex and involve immunological and non-immunological aspects (1). Innate defense mechanisms include low stomach pH, bile salts, peristalsis, mucin layers and antimicrobial compounds, such as lysozyme (2). Immunological mechanisms include specialized lymphoid aggregates, underlying M cells, called peyers' plaques that are distributed throughout the small intestine and colon (3). Luminous antigens presented at these sites result from the stimulation of suitable subsets of T and B cells with the creation of cytokine networks and secretion of antibodies to the gastrointestinal tract (4). In addition, the presentation of the antigen can occur via epithelial cells to epithelial lymphocytes and to the underlying lamina propria immune cells (5). Consequently, the host invests substantially in immune defense of the gastrointestinal tract. However, as the gastrointestinal mucosa is the largest surface on which the host interacts with the external environment, specific control mechanisms must be available to regulate the immune response to the 90.7 metric tons (100 tons) of food, which pass through the gastrointestinal tract in the course of an average life. In addition, the digestive tract is colonized by more than 500 species of bacteria, reaching 1011 to 1012 / g in the colon. Thus, these control mechanisms must be able to distinguish non-pathogenic adherent bacteria from invasive pathogens, which could cause significant damage to the host. In fact, the intestinal flora contributes to the defense of the host, competing with the newly ingested pathogenic microorganisms.
[0003] Probiotic bacteria are believed to be more effective when derived from the species to be treated, or from species closely related to it. Therefore, there is a need for probiotic strains derived from pets, to be used for pets, which are different from those derived from humans.
[0004] WO 01/90311 shows probiotic microorganisms isolated from fecal samples obtained from cats, having probiotic activity. However, these bacteria were obtained from fecal samples, and may not be part of the natural intestinal microflora present in the upper portion of the gastrointestinal (GI) tract.
[0005] Consequently, there is a need to obtain strains of bacteria, by isolation from the natural intestinal microflora present in the upper portion of the gastrointestinal tract, which are particularly adapted for cats, and which have been selected for their probiotic properties and ability to survive processing , and incorporating these strains into compositions that are suitable for their use. Declarations of the invention
[0006] According to the invention, an isolated strain of NCIMB 41675 bifidobacterium is provided. The bifidobacterial strain can be in the form of viable cells, the bifidobacterial strain can be in the form of non-viable cells. Bifidobacteria can be isolated from tissue for colonic biopsy of a feline. The bifidobacterial strain can be significantly immunomodulatory after oral consumption. The invention also provides a formulation that comprises a bifidobacterial strain as described in the present invention.
[0007] The formulation may also contain a probiotic material. The formulation may also contain a prebiotic material. The formulation can also comprise an ingestible vehicle. The ingestible vehicle can be a pharmaceutically acceptable carrier such as a capsule, tablet or powder. The ingestible vehicle can be a food product such as an oil suspension, a milk-based suspension, cheese, a cocoa butter-based composition, a sauce and / or yogurt-based composition.
[0008] The invention additionally provides a food that comprises a bifidobacterial strain or a formulation as described in the present invention.
[0009] The food can be a dry food. The food can be moist food. The food may also contain a probiotic material. The food may also contain a prebiotic material. The food can be a pet food.
[0010] The invention also provides a bifidobacterial strain, or a formulation, or a food, as described in the present invention, for use as a medicament.
[0011] The invention also provides a bifidobacterial strain, or a formulation, or a food, as described in the present invention, for use in the prophylaxis and / or treatment of undesirable inflammatory activity.
[0012] The invention also provides a bifidobacterial strain, or a formulation, or a food, as described in the present invention, for use in the prophylaxis and / or treatment of undesirable gastrointestinal inflammatory activity.
[0013] The invention also provides a bifidobacterial strain, or a formulation, or a food, as described in the present invention, for use in the prophylaxis and / or treatment of autoimmune disorders due to undesirable inflammatory activity.
[0014] The invention also provides a bifidobacterial strain, or a formulation, or a food, as described herein, for use in the prophylaxis and / or treatment of diarrheal disease due to undesirable inflammatory activity.
[0015] The invention also provides a strain of bifidobacteria, or a formulation, or a food, as described here, for use in regulating or improving the immune system of pets.
[0016] The invention also provides a strain of bifidobacterium, or a formulation, or a food, as described herein, for use in the prophylaxis and / or treatment of autoimmune disease in pets.
[0017] The invention also provides a bifidobacterial strain, or a formulation, or a food, as described herein, for use in the prophylaxis and / or treatment of inflammation in pets.
[0018] We describe a strain of bifidobacterium AH121A (NCIMB 41675) or mutants or variants of it. The strain can be obtained by isolation from the dry and washed feline gastrointestinal tract.
[0019] The mutant can be a genetically modified mutant. The variant may be a naturally occurring variant of bifidobacteria.
[0020] The strain may be a probiotic. It may be in the form of a biologically pure culture. An isolated NCIMB 41675 bifidobacterial strain is also described. Strains of bifidobacteria may be in the form of viable cells. Alternatively, strains of bifidobacteria may be in the form of non-viable cells.
[0021] The general use of probiotic bacteria can be in the form of viable cells. However, this can be extended to non-viable cells, such as dead cultures or compositions containing beneficial factors expressed by probiotic bacteria. This may include microorganisms killed by thermal means or exposure to an altered pH, or subjection to pressure. With non-viable cells, product preparation can be simpler, cells can be easily incorporated into drugs and storage requirements are much less limited than with viable cells. Lactobacilus casei YIT 9018 offers an example of the effectiveness of using heat-killed cells as a method of treating and / or preventing tumor growth, as described in U.S. Patent No. US4347240.
[0022] We also describe the use of bacteria obtainable by isolation from the dried and washed feline gastrointestinal tract, for the maintenance and improvement of the pet's health, as well as compositions comprising said lactic acid-forming bacteria.
[0023] The invention also provides a formulation comprising the bifidobacterial strain, as described herein, the formulation can include another probiotic material, the formulation can include a prebiotic material.
[0024] Bifidobacteria are commensal microorganisms. They have been isolated from the microbial flora of the human gastrointestinal tract. The immune system in the gastrointestinal tract cannot have a pronounced reaction in relation to the members of this flora, since the resulting inflammatory activity would also destroy host cells and tissue function. Therefore, there are some mechanisms by which the immune system can recognize non-pathogenic commensal members of the gastrointestinal flora as being different from pathogenic organisms. This ensures that damage to the host tissue is restricted and that a defensive barrier is still maintained.
[0025] Throughout the specification, the terms mutant, variant and genetically modified include a strain of bifidobacteria whose genetic and / or phenotypic properties are altered compared to the parent strain. Naturally occurring variants of Bifidobacterium longum include spontaneous changes in selectively isolated target properties. The deliberate alteration of properties of the parent strain is carried out by conventional technologies of genetic manipulation (in vitro), such as genetic disturbance, conjugative transfer, etc. The genetic modification includes the introduction of exogenous and / or endogenous DNA sequences in the genome of a bifidobacterial strain, for example, by inserting the bacterial strain into the genome by the vectors, including plasmid DNA, or bacteriophages.
[0026] Natural or induced mutations include at least changes in a single base such as deletion, insertion, transversion or other DNA modifications that may result in alteration of the amino acid sequence encoded by the DNA sequence.
[0027] The terms mutant, variant and genetically modified mutant also include a strain of bifidobacteria that has undergone genetic changes that accumulate in a genome, at a rate that is consistent in nature for all microorganisms and / or genetic changes that occur through spontaneous mutation and / or gene capture and / or gene loss that is not achieved by deliberate (in vitro) manipulation of the genome, but is achieved through the natural selection of variants and / or mutants that provide a selective advantage to sustain the survival of bacteria when exposed to environmental pressures, such as antibiotics. A mutant can be created by the voluntary insertion (in vitro) of specific genes in the genome that do not fundamentally alter the biochemical functionality of the organism, but whose products can be used to identify or select bacteria, for example, resistance to antibiotics.
[0028] A person skilled in the art would recognize that mutant or variant strains of bifidobacteria can be identified by analyzing DNA sequence homology with the parent strain. Bifidobacterial strains having a sequence identity close to that of the parent strain are considered mutant or variant strains. A strain of bifidobacteria with a sequence identity (homology) of 96% or more, such as 97% or more, or 98% or more, or 99% or more with the DNA sequence of the parent can be considered a mutant or variant. The homology of the sequence can be determined using the algorithm of the online program "BLAST" (an algorithm for searching for homology), publicly available at http: //www.ncbi.nlm.nih,gov/BLAST/.
[0029] Mutants of the parent strain also include strains derived from bifidobacteria showing at least 85% sequence homology, such as at least 90% sequence homology, or at least 95% sequence homology to the intergenic spacer polynucleotide sequence ( IGS - intergenic spacer) 16s - 23 s of the parent strain. These mutants may further comprise DNA mutations in other DNA sequences in the bacterial genome. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] The invention will be more clearly understood through the description given below by way of example only, with reference to the attached drawings, in which: - Figure 1 is a photograph of the B. longum AH121A strain grown on a Congo red agar plate; Figure 2 is a bar diagram illustrating the IL-10: IL-12p70 ratio of peripheral blood mononuclear cells (PBMC) stimulated with the strain of Bifidobacterium longum 121A (Bifidobacterium 121A); Figure 3 is a graph illustrating the survival of strain 121A in a low pH environment. The strains were challenged at pH 2.5 for 6 hours and their survival was assessed using the plaque count; Figures 4 to 6 are graphs of cytokine secretions from peripheral blood mononuclear cells (PBMC) cultured in vitro; Figures 7 A to E are line graphs showing the profile of IL-10 induction in PBMC after in vitro stimulation as a function of increasing concentrations of 121A and Bif 35624; Figures 8 A to D are line graphs showing the profile of IL-1β induction in PBMC after in vitro stimulation as a function of increasing concentrations of 121A and Bif 35624; Figures 9 A to D are line graphs showing the profile of IL-6 induction in PBMC after in vitro stimulation as a function of increasing concentrations of 121A and Bif 35624; Figures 10 A to D are line graphs showing the profile of IL-8 induction in PBMC after in vitro stimulation as a function of increasing concentrations of 121A and Bif. 35624; Figure 11 A to D are line graphs showing the induction profile of IL-12 p70 in PBMC after in vitro stimulation as a function of increasing concentrations of 121A and Bif. 35624; Figures 12 A to E are line graphs showing the TNF-α induction profile in PBMC after in vitro stimulation as a function of increasing concentrations of 121A and Bif. 35624; Figures 13 A to C are line graphs showing the IFN-γ induction profile in PBMC after in vitro stimulation as a function of increasing concentrations of 121A and Bif. 35624; Figures 14 A to D are line graphs showing the profile of G-CSF inductions in PBMC after in vitro stimulation as a function of increasing concentrations of 121A and Bif. 35624; Figure 15 is a bar diagram showing the effect of 121A on the secretion of IL-10 and IL-12 p70 by human myeloid type dendritic cells; and Figure 16 is a bar diagram showing the effect of 121A on virgin human CD4 + T cells. DETAILED DESCRIPTION OF THE INVENTION
[0031] A deposit of Bifidobacterium longum AH121A strain was created at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) Ferguson Building, Craibstone Estate, Bucksburn, Aberdeen, AB21 9YA, Scotland, United Kingdom on November 5, 2009 to which it was assigned NCIMB access number 41675.
[0032] A deposit of Bifidobacterium longum UCC 35624 strain was created at the National Collections of Industrial and Marine Bacteria Limited (NCIMB) Ferguson Building, Craibstone Estate, Bucksburn, Aberdeen, AB21 9YA, Scotland, United Kingdom, on 13 January 1999, which NCIMB access number 41003 has been assigned.
[0033] Bifidobacterium longum may be a genetically modified mutant or it may be a naturally occurring variant.
[0034] Preferably, Bifidobacterium longum is in the form of viable cells.
[0035] Alternatively, Bifidobacterium longum may be in the form of non-viable cells.
[0036] For use in the present invention, the term "pet" means a domestic animal. Preferably, the term "pet" means domestic animals such as felines (cats), canines (dogs), rabbits, ferrets, horses, cows or the like. More preferably, the term "pet" means a domestic cat. Lactic acid-forming strains of bifidobacteria
[0037] The first aspect of the present invention comprises a strain of lactic acid-forming bacteria of the genus Bifidobacteria, obtainable by isolation from the dried and washed feline gastrointestinal tract, and presenting a probiotic activity in animals. Probiotics consist of viable or dead microorganisms, processed compositions of microorganisms, their constituents such as proteins or carbohydrates, or purified fractions of bacterial yeasts, which beneficially affect a host. The general use of probiotic bacteria is in the form of viable cells. However, this can be extended to non-viable cells, such as dead cultures or compositions containing beneficial factors expressed by probiotic bacteria. This may include microorganisms killed by thermal means, by exposure to an altered pH, or subjected to pressure. For the purpose of the present invention, the term "probiotics" is intended to include, further, the metabolites generated by the microorganisms of the present invention during fermentation, if they are not separately indicated. These metabolites can be released in the fermentation medium, or they can be stored inside the microorganism. For use in the present invention, the term "probiotic" also includes bacteria, bacterial homogenates, bacterial proteins, bacterial extracts, bacterial yeast supernatants and mixtures of these items, which exercise beneficial functions for the host animal, when administered in a therapeutic dose .
[0038] Lactic acid-forming bacteria of the genus Bifidobacteria, which were obtained by direct isolation from the dry and washed gastrointestinal tract of mammals, were found to be adherent to the GI tract following feeding with viable bacterial cells, and also have an action significant immunomodulatory effect when supplied to animals in their viable, non-viable or fractional forms. Without sticking to the theory, it is believed that bifidobacteria obtainable by isolation from the resected and washed gastrointestinal tract maintain close association with the tissues of the gastrointestinal mucosa. Without sticking to the theory, it is believed that this results in the generation, by the probiotic bifidobacteria of the present invention, of alternative responses in the host, which result in their probiotic action. It has been found that probiotic bacteria obtainable by isolation from the dried and washed gastrointestinal tract can modulate the host's immune system through direct interaction with the mucous epithelium and the host's immune cells. This immunomodulation, together with the traditional mechanism of action associated with probiotic bacteria, that is, the prevention of pathogen adherence to the gastrointestinal tract, through occlusion and competition for nutrients, makes the bifidobacteria of the present invention highly effective probiotic organisms.
[0039] The bifidobacterium of the present invention, obtainable by isolation from dried and washed feline GI traop, has in vitro antimicrobial activity against several pathogenic bacterial strains / species. Without sticking to the theory, it is believed that this in vitro antimicrobial activity indicates the potential for probiotic activity in vivo in animals, preferably pets, such as cats. The lactic acid-forming bacteria of the present invention preferably exhibit microbicidal activity in vitro against Salmonella typhimurium, Listeria monocytogenes, Listeria innocua or Eschericia coli, most preferably a combination of these strains and, even more preferably, all those strains.
[0040] Without adhering to the theory, it is believed that the antimicrobial activity of the lactic acid-forming bacteria of the present invention may be the result of several different actions performed by said bacteria. It was previously suggested in the technique, that several strains of bacteria isolated from fecal samples exert their probiotic effect on the gastrointestinal tract, after their oral consumption by preventing, through occlusion, the attachment of pathogenic organisms to the gastrointestinal mucosa. This requires the oral consumption of "live" or viable bacterial cells in order for a colony of bacteria to establish itself in the gastrointestinal tract. However, it is believed that the bifidobacteria of the present invention, obtainable by isolation from the dried and washed feline GI tract, although exerting a probiotic effect due to occlusion if provided in a viable form, may offer a substantial probiotic effect in their forms both viable and non-viable due to the production, during the in vitro fermentation of one or more substances that inhibit the proliferation of pathogenic microorganisms and / or alter the immunocompetence of the host animal. This form of probiotic activity is desirable, since the bacteria of the present invention can be supplied in the form of viable or non-viable cultures, or as purified fermentation products and still provide a beneficial therapeutic effect to the host animal.
[0041] Preferably, the lactic acid-forming bacteria of the present invention are able to maintain their viability after transit through the GI tract. This is desirable, so that cultures of live bacteria can be administered orally, and for colonization to occur after transit through the esophagus and stomach. Colonization of the intestines by the lactic acid-forming bacteria of the present invention is desirable to provide long-term probiotic benefits to the host. Oral dosing of non-viable cells or isolates purified from them induces temporary benefits, however, since bacteria are non-viable, they are not able to grow and provide a continuous probiotic effect in situ. As a result, this may require the host to be dosed regularly in order to maintain health benefits. In contrast, viable cells capable of surviving gastric transit in their viable form and subsequently colonizing the intestines by adhering to and proliferating on the gastrointestinal mucosa, are capable of providing continuous probiotic effects in situ. Therefore, it is preferred that the lactic acid-forming bacteria of the present invention maintain their viability after being suspended in a pH 2.5 medium for 1 hour. For use in the present invention, the term "maintain viability" means that at least 25% of the bacteria initially suspended in the test medium are viable, using the plate counting method known to those skilled in the art. Preferably, the term "maintaining viability" means that at least 50% of the bacteria initially in suspension are viable. It is desirable that the lactic acid-forming bacteria of the present invention maintain their viability after exposure to a low pH, as this mimics exposure to gastric juices in the stomach and upper intestine in vivo, after oral consumption in animals.
[0042] The strain of lactic acid-forming bacteria of the genus Bifidobacteria, obtainable by isolation from the dried and washed feline gastrointestinal tract, can be used to provide probiotic benefits after oral intake in animals, preferably pets or humans. These probiotic benefits generally maintain or improve the animal's overall health. Non-limiting elements of an animal's health and physiology that benefit, whether by relieving symptoms therapeutically, or preventing diseases by prophylaxis include inflammatory disorders, immunodeficiency, inflammatory bowel disease, irritable bowel syndrome, cancer (particularly those of the gastrointestinal and immune system) ), diarrheal disease, antibiotic-associated diarrhea, appendicitis, autoimmune disorders, multiple sclerosis, Alzheimer's disease, amyloidosis, rheumatoid arthritis, arthritis, joint mobility, diabetes mellitus, insulin resistance, bacterial infections, viral infections, fungal infections , periodontal disease, urogenital disease, surgery-associated trauma, surgery-induced metastatic disease, sepsis, weight loss, weight gain, excessive accumulation of adipose tissue, anorexia, fever control, cachexia, wound healing, ulcers, infection of the gastrointestinal barrier, allergy, asthma, respiratory disorders, Circulatory disorders, coronary heart disease, anemia, blood clotting system disorders, kidney disease, central nervous system disorders, liver disease, ischemia, nutritional disorders, osteoporosis, endocrine disorders, and epidermis disorders, treatment of the gastrointestinal tract is preferred. , including treatment or prevention of diarrhea; regulation of the immune system, preferably the treatment or prevention of autoimmune disease and inflammation; maintaining or improving the health of the skin and / or coating system, preferably treating or preventing atopic skin diseases; mitigating or reducing the effects of aging, including mental awareness and activity levels; prevention of diseases associated with the hypothalamic-pituitary-adrenal axis, and improvement of joint health, and consequently, improvement of mobility.
[0043] 1. Blastogênese de linfócitos: Este ensaio mede a resposta proliferativa in vitro de linfócitos isolados a partir de sangue integral fresco obtido de animais de teste e de controle para diversos mitogênios, e é uma medida da função geral das células T e B. Em resumo, células mononucleares de sangue periférico (CMSPs) são isoladas a partir de sangue integral por meio de métodos Ficoll-Hypaque de centrifugação por densidade, conhecidos pelos versados na técnica. As CMSPs isoladas são lavadas duas vezes em meio celular RPMI 1640 suplementado com HEPES, L-glutamina e penicilina/estreptomicina. As células lavadas são ressuspensas em RPMI 1640 e contadas, e a densidade de células é adequadamente ajustada. As 2xl05 células são expostas a uma gama de concentrações (de 0,1 pg/mL a 100 pg/mL) de diversos mitogênios, exemplos dos quais incluem mitogênio de caruru-de-cacho (Gibco), fitoemaglutinina (Gibco) e concanavalina A (Sigma), em triplicata, durante 72 horas a 37°C e 5% CO2 com 10% de soro fetal bovino (Sigma) . Após 54 horas, as células são pulsadas com 1 µCi H-timidina e coletadas, e as contagens de cintilação são lidas em um TopCount NXT em 72 horas. 2. Atividade de células "Natural Killer": Conforme descrito na patente US n° 6.310.090, este ensaio mede a atividade efetora in vitro de células "natural killer" isoladas a partir de sangue integral fresco de animais de teste e de controle. As células "natural killer" (NK) são um componente da função imune inata de um mamífero. As células de adenocarcinoma de tiróide felino são usadas como células-alvo na avaliação da atividade citotóxica de células NK. Foi anteriormente demonstrado que essa linhagem de células é suscetível à morte por células NK felinas. As células-alvo foram cultivadas em um frasco T75 com 20 niL de meio mínimo essencial (MEM; Sigma Chem. Co., St. Louis, Mo., EUA) suplementado com 10% soro fetal de bezerro (FCS), 100 U/mL de penicilina e 100 pg/mL de estreptomicina. Quando confluentes, as células-alvo foram tripsinizadas, lavadas 3 vezes e ressuspensas a 5xl05 células/mL em meio completo (RPMI- 1640+ 10% FCS+100 U/mL de penicilina+100 10 pg/mL de estreptomicina). Triplicatas de alíquotas de 100 µL das células-alvo foram pipetadas em placas de 96 poços com fundo em U (Costar, Cambridge, Massachussets, EUA) e incubadas durante 8 horas para permitir a aderência das células. Os linfócitos (células efetoras, 100 µL) isolados por meio de separação Ficoll-Hypaque (conforme descrito acima) foram então adicionados às células-alvo para se obter uma razão entre células efetoras e células alvo (E:A) de 10:1. Após 10 horas de incubação em 37 °C, foram adicionados 20 µL de um substrato contendo 5 pg de brometo de 3-(4,5-dimetil tiazol-2-il)-2,5-difenil tetrazólio (MTT). A mistura foi incubada durante 4 horas em 37°C, após os quais o MTT não-metabolizado foi removido por aspiração. Os cristais de formazan foram dissolvidos mediante a adição de 200 µL de etanol a 95%. A densidade óptica (DO) foi medida em 570 nm, utilizando-se um leitor de microplacas. A porcentagem de lise especifica para célula NK foi calculada da seguinte forma: citotoxicidade especifica (%) = 100 x {1 - [(densidade óptica de células-alvo e células efetoras - densidade óptica de células efetoras)/(densidade óptica de células-alvo)]} 3. Resposta de anticorpos a vacinas: Os indivíduos de teste recebem uma matriz (até 5) de vacina após pelo menos 12 semanas de alimentação probiótica ou de controle. As vacinas podem ser uma mistura de vacinas novas e redundantes. Alguns exemplos não-limitadores de conjuntos de vacina que podem ser usados incluem misturas de vacinas preparadas por Fort Dodge Animal Health. Alguns exemplos não-limitadores de vacinas adequadas ao uso na presente invenção incluem cinomose felina, adenovirus, coronavirus, parainfluenza, e parvovirus. A história de vacinação do indivíduo determinará as vacinas a serem utilizadas. Os anticorpos específicos para as vacinas administradas são medidas no sangue durante 3 semanas, sendo comparadas a duração e a intensidade da resposta nos grupos com alimentação de controle e probiótica. 4. Hipersensibilidade de tipo retardado: Um método in vitro, não-invasivo de avaliação do status do sistema imune. Este teste compreende uma injeção intradérmica do mitogênio policlonal fitoemaglutinina (PHA) em combinação com eritrócitos de ovelha, uma vacina multivalente, histamina (100 µL de fosfato de histamina a 0,0275 g/L, Greer, Lenoir, NC, EUA) ou PBS (100 µL de solução salina tamponada com fosfato a 8,5 g/L, Sigma). A resposta imunológica ao antígeno é registrada como espessura da dobra de pele, usando calibres, em intervalos de tempo de 0, 24, 48 e 72 horas após a injeção. Um aumento na espessura da dobra de pele indica uma maior resposta de hipersensibilidade, que deve diminuir mediante o tratamento com as bactérias da presente invenção. The treatment of the disorders presented above can be measured using techniques known to those skilled in the art. For example, inflammatory disorders, including autoimmune disease and inflammation, can be detected and monitored using in vivo immune function tests, such as lymphocyte blastogenesis, "Natural Killer" cell activity, antibody response to vaccines, delayed type hypersensitivity and combinations of these items. Such methods are briefly described in the present invention, but are well known to those skilled in the art. 1. Lymphocyte blastogenesis: This assay measures the in vitro proliferative response of lymphocytes isolated from fresh whole blood obtained from test and control animals to various mitogens, and is a measure of the general function of T and B cells. In summary , peripheral blood mononuclear cells (PBMCs) are isolated from whole blood using Ficoll-Hypaque methods of density centrifugation, known to those skilled in the art. Isolated PBMCs are washed twice in RPMI 1640 cell medium supplemented with HEPES, L-glutamine and penicillin / streptomycin. The washed cells are resuspended in RPMI 1640 and counted, and the cell density is adjusted accordingly. The 2x105 cells are exposed to a range of concentrations (from 0.1 pg / ml to 100 pg / ml) of various mitogens, examples of which include cluster kite (Gibco), phytomagglutinin (Gibco) and concanavalin A (Sigma), in triplicate, for 72 hours at 37 ° C and 5% CO2 with 10% fetal bovine serum (Sigma). After 54 hours, cells are pulsed with 1 µCi H-thymidine and collected, and scintillation counts are read on a TopCount NXT in 72 hours. 2. "Natural Killer" cell activity: As described in US Patent No. 6,310,090, this assay measures the in vitro effector activity of "natural killer" cells isolated from fresh whole blood from test and control animals. Natural killer cells (NK) are a component of a mammal's innate immune function. Feline thyroid adenocarcinoma cells are used as target cells in the evaluation of the cytotoxic activity of NK cells. This cell line has previously been shown to be susceptible to death by feline NK cells. The target cells were cultured in a T75 flask with 20 niL of minimal essential medium (MEM; Sigma Chem. Co., St. Louis, Mo., USA) supplemented with 10% fetal calf serum (FCS), 100 U / ml of penicillin and 100 pg / ml of streptomycin. When confluent, the target cells were trypsinized, washed 3 times and resuspended at 5x10 5 cells / ml in complete medium (RPMI-1640+ 10% FCS + 100 U / ml penicillin + 100 10 pg / ml streptomycin). Triplicates of 100 µL aliquots of the target cells were pipetted into 96-well plates with a U-bottom (Costar, Cambridge, Massachusetts, USA) and incubated for 8 hours to allow the cells to adhere. Lymphocytes (effector cells, 100 µL) isolated by Ficoll-Hypaque separation (as described above) were then added to the target cells to obtain a 10: 1 ratio between effector cells and target cells (E: A). After 10 hours of incubation at 37 ° C, 20 µL of a substrate containing 5 pg of 3- (4,5-dimethyl thiazol-2-yl) -2,5-diphenyl tetrazolium bromide (MTT) was added. The mixture was incubated for 4 hours at 37 ° C, after which the non-metabolized MTT was removed by aspiration. The formazan crystals were dissolved by adding 200 µL of 95% ethanol. The optical density (OD) was measured at 570 nm, using a microplate reader. The percentage of specific lysis for NK cells was calculated as follows: specific cytotoxicity (%) = 100 x {1 - [(optical density of target cells and effector cells - optical density of effector cells) / (optical density of cells- target)]} 3. Antibody response to vaccines: Test subjects receive a matrix (up to 5) of vaccine after at least 12 weeks of probiotic or control feeding. Vaccines can be a mix of new and redundant vaccines. Some non-limiting examples of vaccine sets that can be used include vaccine mixtures prepared by Fort Dodge Animal Health. Some non-limiting examples of vaccines suitable for use in the present invention include feline distemper, adenovirus, coronavirus, parainfluenza, and parvovirus. The individual's vaccination history will determine which vaccines to use. The specific antibodies for the vaccines administered are measured in the blood for 3 weeks, and the duration and intensity of the response in the control and probiotic feeding groups are compared. 4. Delayed type hypersensitivity: A non-invasive in vitro method of assessing the status of the immune system. This test comprises an intradermal injection of polyclonal phytohemagglutinin (PHA) mitogen in combination with sheep erythrocytes, a multivalent vaccine, histamine (100 µL of histamine phosphate at 0.0275 g / L, Greer, Lenoir, NC, USA) or PBS (100 µL of phosphate buffered saline at 8.5 g / L, Sigma). The immune response to the antigen is recorded as skin fold thickness, using gauges, at intervals of 0, 24, 48 and 72 hours after injection. An increase in the thickness of the skin fold indicates a greater hypersensitivity response, which should decrease with treatment with the bacteria of the present invention.
[0044] Additional methods for determining the effect of the bifidobacterial bacteria of the present invention are described in US 6,133,323 and US 6,310,090.
[0045] In addition, the improvement in the effects of aging can be determined by using dual emission X-ray absorptometry or computed tomography to measure body composition, including fat body mass, lean body mass and bone mineral content. Similarly, this method can be used to determine changes in anatomy such as weight loss or bone density in individuals after infection.
[0046] The bifidobacteria of the present invention can also be used in a method for reducing stress levels in pets. Blood concentrations of stress hormones, including epinephrine, norepinephrine, dopamine, cortisol and C-reactive protein and other acute phase proteins can be measured to determine stress levels and their reduction or maintenance. These hormones are recognized stress biomarkers, and can be readily measured using techniques known to those skilled in the art. In addition, direct measurement of adrenal size as an in vivo marker of hypothalamic-pituitary-adrenal axis activity can be performed using computed tomography images.
[0047] In addition, the maintenance or improvement of the health of the skin and / or coat of pets, including atopic skin disease, can be measured through the use of skin and coat assessments conducted by two trained individuals. Examples of criteria analyzed during the evaluation include: a) hair loss index: A hair loss index is assigned to each test subject by collecting hair produced during the standard brushing session. Hair is retained and weighed, and control and test subjects are compared, b) Subjective skin / coat assessments: Subjectively trained examiners assess the condition of the skin and coat, assessing hair loss, dandruff, shine, uniformity, softness and density , c) Functional skin assessment: The skin barrier function can be assessed by wiping the skin surface with a gauze pad soaked in acetone. This technique effectively disrupts the skin's barrier function by removing individual cell layers from the corneal layer, along with the associated lipid fractions. Barrier disturbance is quantified by measuring the increase in transepidermal water loss (PTEA) and the degree of redness of the offended site, using methods known to those skilled in the art. The scores for redness (erythema) are obtained using the camera and lighting system described above. PTEA records and redness scores are obtained immediately before and after the disturbance, as well as at the end points at five and 24 hours, to assess the protective and healing properties of the skin.
[0048] In addition, the treatment of gastrointestinal infections in pets may include optimizing their microbial ecology. The optimization of microbial ecology in pets preferably involves reducing the levels of pathogenic bacteria in their feces. The levels of pathogenic bacteria present in pet feces can be listed using the standard plate counting method, known to those skilled in the art. Most preferably, the pathogenic bacteria are selected from the group consisting of Clostridia, Escherichia, Salmonella, bacteroids and combinations thereof. Some non-limiting examples of suitable strains of pathogenic bacteria include C. perfringens, C. difficile, Eschericia coli, Salmonella typhimurium and combinations thereof.
[0049] The method of using the bacteria of the present invention may also include prophylactic or therapeutic treatment of the urinary tract of mammals, preferably pets. Some non-limiting examples of urinary tract treatments include treating or preventing urinary tract infections, treating or preventing kidney diseases, including urinary tract stones, treating or preventing bladder infections, and the like. Without sticking to the theory, it is believed that the bifidobacterial bacteria of the present invention are useful in preventing these diseases, as a result of their ability to degrade oxalic acid, as demonstrated in vitro. Oxalic acid is a by-product of urinary metabolism that can form insoluble precipitates that result in kidney, bladder and other urinary tract infections. Through degradation of oxalic acid and, therefore, potentially preventing its precipitation and accumulation in the urinary tract, the bacteria of the present invention can treat and prevent infections and other diseases of the urinary tract. Oxalic acid degradation can be measured in vitro using the cat 755699 oxalic acid test kit, available commercially from Boehringer Mannheirn / R-Biopharm.
[0050] The bifidobacteria of the present invention can be used in a method for improving or maintaining the health of pets, comprising improving fiber digestion. The improvement of fiber digestion is desirable, as it promotes the proliferation of said probiotic bacteria, as well as beneficial endogenous microflora, which helps in the suppression of some potentially pathogenic bacteria. In addition, a decrease in the amount of toxic metabolites and harmful enzymes that result from colonic fermentation has been documented in humans (6). Fiber digestion can be determined using the method described in Vickers et al. (7), except that instead of inoculating using diluted fecal samples, each experiment used pure cultures of the bacterial strains in question.
[0051] The feline probiotic strains of the present invention can be used to reduce the odor of feces and urine and, concurrently, in the litter box, by reducing the production of compounds, in feces and urine, which cause odor. Some non-limiting examples of odor-causing compounds include ammonia, indoles, phenols, amines, branched-chain fatty acids and volatile sulfur-containing compounds. Without sticking to the theory, it is believed that reducing the content of these compounds in a pet's feces or urine reduces the odor associated with them. In addition, for pets that use a litter box, there is a concomitant decrease in the odor of the litter box.
[0052] The method of using the lactic acid-forming bacteria of the present invention typically involves oral consumption by the animal. Oral consumption can occur as part of normal dietary intake, or as a supplement to it. Oral consumption typically occurs at least once a month, preferably at least once a week and, more preferably, at least once a day. The lactic acid-forming bacteria of the present invention can be administered to the pet in an amount therapeutically effective to maintain or improve the health of the animal, preferably a pet. For use in the present invention, the term "therapeutically effective amount", with respect to lactic acid-forming bacteria, means that amount of bacteria that is sufficient to provide the desired effect or benefit to a host animal in need of treatment, but low the sufficient to avoid adverse effects such as toxicity, irritation or allergic response, in proportion to a reasonable risk / benefit ratio when used in the manner indicated in the present invention. The specific "therapeutically effective" amount will vary according to factors such as the specific condition being treated, the physical condition of the user, the duration of treatment, the nature of the simultaneous therapy (if any), the specific dosage form to be used, the vehicle employed, the solubility of the dosage form, and the specific dosage regime.
[0053] Preferably, lactic acid-forming bacteria are supplied to the pet at a dose in the range of 1.0E + 04 to 1.0E + 14 CFU per day and, more preferably, in the range of 1.0E + 06 to 1.0E + 12 UFC per day. The composition may preferably contain at least 0.001% lactic acid-forming bacteria of the genus Bifidobacteria, in the range of 1.0E + 04 to 1.0E + 12 CFU / g, obtainable by isolation from the dried feline GI tract and washed. The lactic acid-forming bacteria can be administered to the animal in its viable form, in the form of dead cells, or as distillates, isolates or other fractions of the lactic acid-forming bacteria fermentation products of the present invention, or any mixture thereof. .
[0054] Preferably, lactic acid-forming bacteria, or a purified or isolated fraction thereof, are used to prepare a composition for maintaining or improving the health of an animal. As indicated above, the composition may be part of the normal dietary intake, or it may be a supplement. In cases where the composition is part of the normal dietary intake, it may be in the form of a dry food for animals, such as cookies or feed, a food based on processed grains, a wet food for animals, yogurts, sauces, items chewy, snacks and the like.
[0055] These compositions can comprise other components. Other components are beneficial for inclusion in the compositions used in the present invention, but are optional for the purposes of the invention. For example, food compositions are preferably nutritionally balanced. In one embodiment, the food compositions may comprise, based on dry matter, from about 20% to about 50% and, preferably, from about 22% to about 40% crude protein, by weight of the food composition . The crude protein material can comprise any material having a protein content of at least about 15% by weight, some non-limiting examples of which include vegetable proteins such as soybeans, cottonseed and peanuts, and animal proteins such as casein , albumin and meat tissue. Some non-limiting examples of meat tissue useful in the present invention include fresh meat and dried or processed flours, such as fish meal, poultry meal, meat meal, bone meal and the like. Other types of suitable sources of crude protein include wheat or corn gluten, and proteins extracted from microbial sources, such as yeast.
[0056] In addition, food compositions may comprise, based on dry matter, from about 5% to about 35% and preferably from about 10% to about 30% fat, by weight of the food composition. In addition, food compositions comprising the lactic acid forming bacteria of the present invention may also comprise from about 4% to about 25% of total dietary fiber. The compositions can also comprise multiple sources of starch, as described in WO99 / 51108.
[0057] The compositions of the present invention can also contain a carbohydrate source. Illustrative sources are grains or cereals such as rice, corn, corn, sorghum, barley, alfalfa, wheat and the like. In addition, the compositions may also contain other materials, such as dry whey and other dairy by-products.
[0058] Compositions comprising the bacteria of the present invention can also comprise a prebiotic. The term "prebiotic" includes substances or compounds that are fermented by the pet's intestinal flora and, consequently, promote the proliferation or development of lactic acid-forming bacteria in the gastrointestinal tract of said animal, to the detriment of pathogenic bacteria. The result of this fermentation is a release of fatty acids, in particular short-chain fatty acids, into the colon. This has the effect of reducing the pH value in the colon. Some non-limiting examples of suitable prebiotics include oligosaccharides, such as inulin and its hydrolysis products commonly known as fructooligosaccharides, ga1actoo1igosaccharides, xylooligosaccharides or starch oligoderivatives. Prebiotics can be supplied in any suitable form. For example, the prebiotic can be supplied in the form of material of plant origin containing these fibers. Suitable plant-based materials include asparagus, artichokes, onions, wheat or chicory, as well as residues of these plant-based materials. Alternatively, prebiotic fiber can be supplied in the form of an inulin extract, for example, chicory extracts are suitable. Suitable inulin extracts can be obtained from Orafti SA of Tirlemont 3300, Belgium, under the trademark "Raftiline". For example, inulin can be supplied in the form of Raftiline (g) ST, which is a fine white powder that contains from about 90% to about 94% by weight of inulin, up to about 4% by weight , glucose and fructose, and about 4% to 9% by weight of sucrose.
[0059] Alternatively, the fiber may be in the form of a fructooligosaccharide such as that obtained from Orafti SA de Tirlemont 3300, Belgium, under the trademark "Raftilose". For example, inulin can be supplied in the form of supplied in the form of Raftilose (g) P95. Otherwise, fructooligosaccharides can be obtained by hydrolysis of inulin using enzymatic methods, or by using microorganisms.
[0060] For dry pet food, a suitable process is extruded cooking, although baking and other suitable processes can be used. When cooked with extrusion, dry pet food is usually provided in the form of a feed. If a prebiotic is used, it can be mixed, before processing, with the other ingredients of the dry pet food. A suitable process is described in European patent application No. 0850569. If a probiotic microorganism is used, it is best that it is applied as a coating or filling to the dry pet food. A suitable process is described in European patent publication EP 0 862 863.
[0061] For wet foods, the processes described in US patents No. 4,781,939 and 5,132,137 can be used to produce simulated meat products. Other procedures for producing chunky products can also be used, for example, cooking in a steam oven. Alternatively, fillet products can be produced by emulsifying a suitable meat material to produce a meat emulsion, adding a suitable gelling agent and heating said meat emulsion, before packaging it in cans or other containers . Typical wet food compositions can comprise from about 5% to about 15% protein, from about 1% to about 10% fat, and from about 1% to about 7% fiber. Non-limiting examples of ingredients that can be used in wet food compositions include chicken, turkey, beef, white fish, chicken broth, turkey broth, beef broth, chicken liver, rice chili, corn grits, fish meal, eggs, beet pulp, chloride, flaxseed bran, lamb, beef by-products, chicken by-products and mixtures thereof. In another embodiment, supplement compositions such as cookies, chewable items and other snacks can comprise, based on dry matter, from about 20% to about 60% protein, or from about 22% to about 40% protein. protein, by weight of the supplement composition. As another example, supplement compositions may comprise, based on dry matter, from about 5% to about 35% fat, or from about 10% to about 30% fat, by weight of the supplement composition . Food and supplement compositions intended for use by felines are common knowledge in the art.
[0062] Pet foods may contain other active agents such as long-chain fatty acids and zinc. Some suitable examples of long-chain fatty acids include alpha-linoleic acid, gamma-linolenic acid, linoleic acid, eicosapentaenoic acid, and docosahexanoic acid. Fish oils are an adequate source of eicosapentanoic acids and docosahexanoic acid.
[0063] Borage oil, blackcurrant seed oil and primula oil are suitable sources of gamma-linolenic acid. Safflower oils, sunflower oils, corn oils and soy oils are suitable sources of linoleic acid. These oils can also be used on the coating substrates mentioned above. Zinc can be supplied in a number of suitable ways, for example as zinc sulfate or zinc oxide. In addition, many ingredients commonly used in pet food are sources of fatty acids and zinc. It has been observed that the combination of chicory, as a source of prebiotic, with an oil rich in linoleic acid, such as soybean oil, provides unexpected benefits that suggest a synergistic effect.
[0064] In cases where the composition is in the form of a sauce, it preferably comprises at least 10% of a broth, some non-limiting examples of which include vegetable, beef, chicken or ham broths. . Typical dressing compositions can comprise from about 0.5% to about 5% crude protein, from about 2% to about 5% crude fat, and from about 1% to about 5% fiber .
[0065] Some other non-limiting examples of supplements suitable for use in the present invention include powders, oil suspensions, milk and cheese based suspensions, and cocoa butter based compositions as well as pills or capsules. In cases where the composition is in the form of a pill, suitable binding agents are necessary to maintain the pill in a solid and compressed form. Some non-limiting examples of suitable binding agents include natural gums such as xanthan gum, pectins, lecithins, alginates and others known to those skilled in the art. In cases where the composition is in the form of a capsule, it is preferably encapsulated using technologies known to those skilled in the art. Some non-limiting examples of suitable encapsulation materials include polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), alginates and gelatin. Yogurt-based compositions can comprise from about 1% to about 5% protein, from about 10% to about 20% carbohydrate, from about 1% to about 5% fiber, from about 1% to about 5% fat and from about 50% to about 90% of a liquid vehicle, such as milk. EXAMPLES
[0066] These examples are provided to illustrate the invention, and are not intended to limit the scope of the invention in any way. Example 1 - Isolation of Bifidobacterium longum AH121A
[0067] The strain of Bifidobacterium longum AHl21a was isolated from the intestinal tissue of a feline.
[0068] Samples of feline intestines were obtained from healthy cats presented to local veterinarians for euthanasia initiated and approved by animal owners. All animals were healthy and disease free. The colon, middle colon, cecum and ileum of each cat were dissected in order to expose the mucosa.
[0069] The supernatants were removed after shaking the mucous tissue (in a vortex for 1 minute) and mechanical homogenization of the tissue. Each supernatant was placed on a Mann Rogosa Sharpe (MRS) type agar plate. These were incubated anaerobically, using an Anerocult GasPak system, for 48 hours at 37 ° C. Colonies isolated from the plates were reapplied by smearing in MRS, and again cultured anaerobically under the same conditions. The isolated colonies were reapplied by smearing 4 more times, in order to purify a single strain. The colony's morphology and microscopic appearance were evaluated. Suitable isolates were tested for Gram reaction and catalase activity. The identification of Gram-positive rods, catalase negative, was performed using API test (API 5 OCHL, BioMerieux). The harvested cells were washed twice with 0.05 M phosphate buffer (pH 6.5) and cysteine HCl (500 mg / L), washing followed by sonication. Cell fragments were removed by centrifugation. Supernatants were incubated with NaF (6 mg / ml) and Na iodoacetate (10 mg / ml) for 30 minutes at 37 ° C. The reaction was stopped by incubation with hydroxylamine HCl (pH 6.5) for 10 minutes at room temperature. Color development was monitored after the addition of HCl (4M), FeC13.6H20, (5% (w / v) in 0.1M HCl) and fructose-6-phosphate (Na salt). The formation of acetyl phosphate from fructose-6-phosphate was evidenced by the reddish color formed by the ferric chelate of its hydroxide. Species identification
[0070] The 16s sequencing of the intergenic spacer (IGS) was performed to identify the isolated bifidobacterial species. In short, DNA was isolated from AH121A using 100 µL of extraction solution and 25 µL of tissue preparation solution (Sigma, XNAT2 Kit). The samples were incubated for 5 minutes at room temperature, followed by 2 h at 95 ° C and then 100 µL of neutralization solution (XNAT2 kit) was added. The genomic DNA solution was quantified using a Nanodrop spectrometer and stored at 4 ° C. PCR was performed using the IGS, IGS L: 5'- GCTGGATCACCTCCTTTCT-3 'primers (SEQ ID No. 3) which resulted in the identification of SEQ ID No. 1 and IGS R: 5'-CTGGTGCCAAGGCATCCA-3' ( SEQ ID No. 4) which resulted in the identification of SEQ ID No. 2. The cycle conditions were 94 ° C for 3 minutes (1 cycle), 94 ° C for 30 seconds, 53 ° C for 30 seconds, 72 ° C for 30 seconds (28 cycles). The PCR reaction contained 4 µL (50 ng) of DNA, PCR mixture (XNAT2 kit), 0.4 µM of IGS L and R primer (MWG Biotech, Germany). The PCR reactions were performed on an Eppendorf thermocycle. The PCR products (10 µL) were passed, together with a molecular weight marker (100 bp Ladder, Roche) on a 2% agarose gel stained with ethidium bromide (EtBr) in TAE (EDTA tris-acetate), to determine the IGS profile. PCR products from bifidobacteria (single band) were purified using the Promega Wizard PCR purification kit. The purified PCR products were sequenced using primers (above) for the intergenic spacer region (IGS). The sequence data was then searched against the NCBI's nucleotide database to determine the strain's identity by nucleotide homology. The resulting DNA sequence data was submitted to the nucleotide-nucleotide homology BLAST search tool (http://www.ncbi.nlm.nih.gov/BLAST/). The closest match for the string was identified and then the strings were aligned for comparison using DNASTAR MegAlign software. The sequences (SEQ ID No. 1 [IGS forward sequence] and SEQ ID No. 2 [IGS reverse sequence]) obtained can be seen in the sequence listing. The search in the NCIMB database revealed that AH121A has a unique IGS sequence (SEQ ID No. 1 [forward sequence] and SEQ ID No. 2 [reverse sequence]) with its sequence homology closest to a Bifidobacterium longum. Example 2 - Congo red agar screen
[0071] A Congo red agar screen was used to phenotypically evaluate strains of bacteria that express extracellular polysaccharide (EPS - extracellular polysaccharide). In short, 10 mL of modified Rogosa broth medium (+ 0.05% cysteine) was inoculated aseptically with a colony recently grown from the bacterial strain and incubated anaerobically at 37 ° C until turbid (about 16 to about 24 hours). The broth cultures were aseptically applied by smearing the Congo red agar plates and incubated anaerobically at 37 ° C for 48 hours. EPS produced as a by-product of the growth and / or metabolism of certain strains is believed to prevent the absorption of Congo red dye resulting in a crertie / white colony morphology. Dyes that produce less EPS easily absorb the Congo red dye, resulting in a pink / red colony morphology. Strains that do not produce a red color of EPS appear almost transparent on a background of red agar.
[0072] With reference to figure 1, the morphology of the bright white colonies of B. logum AH121A is convex and mucoid. Example 3
[0073] Determination of the resistance of strains of AHF121A bacteria isolated from feline to various concentrations of pig bile and to evaluate the survival of bacterial AHF121A isolated at pH 2.5 for 6 hours, and the resistance to subsequent bile with the use of various concentrations of bile . Experimental project:
[0074] The test strain was Bifidobacterium longum AHF121A. Bile resistance is examined using MRS / RCA agar plates supplemented with pork bile (0.3, 0.5, 1.0, 2.0, 5.0, 7.5 and 10%). Strain survival at pH 2.5 is monitored at -5, 5, 30, 60, 120, 180 and 360 min intervals using the plate counting method. Bile resistance is examined after challenging the strains at pH 2.5 for 6 h. Method:
[0075] The procedure for determining resistance to feline bile is defined below.
[0076] An evaluation of the survival rate of lyophilized bacteria in the presence of various concentrations of feline bile, in the range of 0.3% to 10%.
[0077] Plates of synthetic feline bile of various concentrations were prepared by preparing 45% synthetic bile broth solution, heat treatment of the bile broth at 80 ° C for 10 minutes to kill any vegetative cells.
[0078] The various concentrations of bile used were: 2% = 6.67 mL of bile broth + 143.33 of suitable agar 1% = 3.33 mL of bile broth + 146.67 mL of agar 0.5% = 1.67 mL of bile broth + 148.33 mL of agar
[0079] For each dilution, the undesirable molten agar was removed after the autoclave and replaced with the appropriate volume of bile broth.
[0080] The bile plates were prepared daily, but could be stored for up to a week.
[0081] The colony forming unit (CFU / g) of each lyophilized test dye was quantified by the plate spreading technique.
[0082] The test strains were stained on pig bile plates by resuspending 109 CFU / mL of lyophilized strains in 10 mL of sterile PBS, dividing the pork bile plates into ¼ and staining 4 strains (10 µL) /he scores.
[0083] The plates were dried for 30 min (or until the stain was dried on the agar) and incubated under suitable conditions.
[0084] The procedure for assessing the survival rates of strains of bacteria in a low pH (pH 2.5) environment is described below.
[0085] The enumeration of lyophilized powders was performed using the plate spreading technique. The medium was acidified by adding 6 M HCl to 100 mL of broth to adjust the pH to 2.5. The volume needed to make the adjustment was noted and with the use of sterile techniques, the pH 4 x 100 mL of MRS broth (remaining broth) was adjusted with the use of equal volumes of acid. The CFU / g of each lyophilized test dye was quantified using the plate spreading technique. 109 CFU / mL of lyophilized bacteria were resuspended in an acidified medium and incubated under appropriate anaerobic conditions. Survival was measured by removing aliquots at 5, 30, 60, 120, 180, 240 and 360 min and determining the CFU / ml using plate spreading techniques. Results:
[0086] Table 1. Growth of bacterial isolates in the presence of feline bile
[0087] Table 1 demonstrates the effect of feline bile on the growth of the strain. The feline bacterial strain was able to tolerate ≤ concentrations of 2% feline bile, o Figure 3 shows acid tolerance at pH 2.5. Example 4 - Effect of 121A on the IL-10: IL-12 ratio
[0088] Peripheral blood mononuclear cells (PBMCs) were isolated from healthy peripheral human blood using CPT tubes, BD Vacutainer (BD catalog 3627 61), according to the manufacturer's instructions. PBMCs were washed and resuspended in Dulbecco's modified Eagle - Glutamax ™ medium (Glutamax (substituted glutamine) + pyruvate + 4.5 g / L glucose (Gibco catalog 10569-010) 10% fetal bovine serum (Sigma catalog F4135), and 1% penicillin / streptomycin (Sigma catalog P0781). PBMCs were incubated (2 x 105 cells per well) in 96-well flat-bottom plates and 20 µL of a bacterial suspension (at a concentration of 1 x 107 CFU / mL) PBMCs were matched with bacteria for 48 hours at 37 ° C / 5% CO2 in an incubator.After the 2-day incubation period, the plates were centrifuged at 300 xg, and the supernatants were removed and stored frozen at -80 ° C until analysis The levels of interleukin-10 (IL-10) and interleukin-12p70 (IL-12p70) in the supernatant cultures were quantified using a 96-well assay kit available from Meso Scale Discovery (Gaithersburg, MD, USA; catalog K15008B-1)
[0089] The bacteria were prepared for co-culture experiments in two formats: (a) The newly grown bacteria were grown in Difco MRS medium and harvested shortly after entering the stationary phase. All cells were cultured under anaerobic conditions at 37 ° C. (b) The bacteria were grown under anaerobic conditions at 37 ° C in Difco MRS medium and harvested shortly after entering the stationary phase. Lyophilized powders were generated for each of these bacteria and stored at -80 ° C in flasks with 100 mg aliquots. Immediately before use, an aliquot of each strain was removed from the freezer and left outdoors until it reached room temperature. Each strain was washed 3 times in 10 ml of Ringer's solution followed by centrifugation. A new bottle was used on each occasion. Growth curves (optical density (OD) vs number of living cells) were constructed for each growth condition, and the washed cells were normalized by the number of cells prior to addition to PBMCs. A bacteria-free control was also included in all experiments. All tests were performed in triplicate.
[0090] Figure 2 illustrates the effect of strain 121A on IL-10: IL-12 induction. Both freshly grown and freeze-dried cultures had a similar effect. Example 5 - Effect of 121A on IL-10 secretion
[0091] The appropriate immune response to microbes is an important determinant of the host's overall health. Excessive responses can lead to inflammatory diseases (eg, colitis) while inadequate responses can lead to persistence and spread of the pathogen. The immunological assays described here are well described in the literature as useful methods for determining host immunological activity in response to specific microbes found.
[0092] Human peripheral blood mononuclear cells (PBMCs), which contain monocytes, dendritic cells, B cells and T cells, were obtained from healthy volunteers and stimulated in vitro with each bacterial strain. The culture supernatants were then removed and the cytokine levels quantified.
[0093] IL-10 is a very important cytokine for controlling aberrant proinflammatory immune responses. Animals IL-10 KO develop colitis and gastrointestinal tumors while regulatory cells in the immune system secrete and use IL-10 to control potentially harmful immune responses. Thus, the increased secretion of this cytokine would protect against inappropriate inflammatory activity and excessive immune responses to pathogens.
[0094] The secretion of IL-10, in vitro from cultured peripheral blood CMSPs, mononuclear cells was determined 48 hours after coincubation with each bacterial strain. The strains induced secretion of IL-10 and similar levels of IL-10 were observed for AHF121A and 35624. (Figures 4 to 6). Example 6: A Bif. AH121a has immunomodulatory activity when combined with human immune system cells in vitro, different from those of Bif. AH35624. Materials & Methods
[0095] Infant Bifidobacteriums longum strain UCC35624 (B624) and Bifidobacteriumrias longum 121a strain are tested with the cytokine induction assay CMSP. The bacteria are prepared for co-culture experiments in the following formats. The bacteria are grown under anaerobic conditions at 37 ° C in Difco MRS medium and harvested shortly after entering the stationary phase. Lyophilized powders are generated for each of these bacteria and stored at -80 ° C and vials of 100 mg aliquots. Immediately before use, an aliquot of each strain was removed from the freezer and left outdoors until it reached room temperature. Each strain was washed 3 times in 10 ml of Ringer's solution followed by centrifugation. A new bottle is used on each occasion.
[0096] Direct microscopic counts are performed using a Petrof f-Hausser counting chamber according to the manufacturer's instructions and the washed cells normalized by the number of cells before addition to the PBMC assay. The bacteria (20 µL in phosphate buffered saline (PBS - phosphate buffered saline)) are added to each PBMC well to give the total number as indicated for each experiment. Cytokine induction assay in PBMC (peripheral blood mononuclear cells)
[0097] Peripheral blood mononuclear cells (PBMCs) are isolated from healthy human peripheral blood using BD Vacutainer CPT tubes (cell catalog 362761), according to the manufacturer's instructions. PBMCs are washed and resuspended in Dulbecco's modified Eagle's Glutamax TM (Glutamax (glutamine substitute) + pyruvate + 4.5 g / L glucose (Gibco catalog 10569-010) 10% fetal bovine serum (Sigma catalog F4135), and 1% penicillin / streptomycin (Sigma catalog P0781). PBMCs are incubated (2 x 105 cells per well) in 96-well bottom plates and 20 µL of a bacterial suspension (with concentration ranges between 1 x 106-8 CFU / mL) added up to 6 bacterial samples are tested: 2.5E + 08, 1.0E + 08, 5.0E + 07, 2.5E + 07, 1.0E + 07, and 1.0E + 06. A control without bacteria is also done, all tests are performed in triplicate.After a 2-day incubation at 37 ° C, the plates were rotated at 300 xg, and the supernatants were removed and stored frozen at -80 ° C until analysis PBMCs are matched with bacteria for 48 hours at 37 ° C / 5% CO2 in an incubator.The cytokines in the culture supernatants are tested using a 96-well assay kit available j linked to Meso Scale Discovery (Gaithersburg, MD, USA; catalog K15008B-1). Human interleukin 1 beta (Β-1β), Human interleukin 6 (Il-β), Human interleukin 8 (Il-8), Human interleukin 10 (Il-10), Human interleukin 12p70 (Il12p70), Human interferon-gamma (IFN -γ), human tumor necrosis factor alpha (TNFoα) and human G-CSF are quantified and recorded as picograms per milliliter (pg / mL). Each sample is tested in 3 to 5 replicates (A to E). Results of
[0098] The UCC35624 children's Bifidobacterium longum strain (B624) and the Bifidobacterium longum 121a strain are tested for immunomodulation with the use of cytokine induction assay in PBMC to generate extended dose response curves with up to 6 different amounts of bacteria tested: 2.5E + 08, 1.0E + 08, 5.0E + 07, 2.5E + 07, 1.0E + 07, and 1.0E + 06. Supernatants are tested for a range of cytokines, including IL-1β, -6, -8, -10 and -12, TNF-α, IFN-γ and G-CSF. The cytokine measurement is represented as the mean (+/- standard deviation from the mean (DPM)) of up to 5 individual donors (A to E).
[0099] In comparison to 35624, strain 121a showed a very similar pattern for inducing most cytokines including IL-10, but a very different pattern and increased production of IL-6 and IL-8.
[0100] IL-10: The 121a incubation induces a dose-responsive increase in the anti-inflammatory cytokine IL-10 in PBMC after in vitro stimulation (figure 7). The induction of IL-10 is qualitatively and quantitatively similar to the incubation with 35624. The maximum induction of IL-10 does not appear to be achieved with up to 1.00 x 109 bacteria per well. IL-1β: The 121a incubation induces a dose-responsive increase in the proinflammatory cytokine IL-Ιβ in PBMC after in vitro stimulation (figure 8.) IL-Ιβ induction is qualitatively and quantitatively similar to the 35624 incubation. maximum induction of IL-10 does not appear to be achieved with up to 1.0 x 109 bacteria per well. IL-6: Incubation with 121a induces a dose-responsive increase in cytokine IL-6 in PBMC after in vitro stimulation (figure 9). Quantitatively the pattern is different with 121a when compared to 35624; with higher levels of IL-6 measured with 121a specifically at lower doses of bacteria per well. IL-8: Incubation with 121a induces a dose-responsive increase in the cytokine IL-8 in PBMC after in vitro stimulation (figure 10). Quantitatively the pattern is different with 121a when compared to 35624; with higher levels of IL-8 measured with 121a at all bacterial doses per well. IL-12: Incubation with 121a induces a dose-responsive increase in the proinflammatory cytokine IL-12 in PBMC after in vitro stimulation (figure 11). The IL-12 modulation pattern is bell-shaped with 121a and 35624, increasing to peak levels and then decreasing with higher bacterial concentrations. Quantitatively the pattern is somewhat variable for IL-12, but generally similar to 121a when compared to 35624. TNF-α: Incubation with 121a induces a dose-responsive increase in cytokine. pro-inflammatory TNF-α in PBMC after in vitro stimulation (figure 12). The induction of TNF-α is qualitatively and quantitatively similar to the incubation with 35624 for 3 of 5 replicates, with higher levels of TNF-α found in 2 of 5 replicates (See C and E). Maximum IL-10 induction appears to be achieved with up to 1.0 x 108 bacteria per well. INF-γ: Incubation with 121a induces a dose-responsive increase in the pro-inflammatory cytokine INF-γ in PBMC after in vitro stimulation (figure 13). Quantitatively the pattern is somewhat variable for INF-γ, but generally similar to 121a when compared to 35624. G-CSF: The 121a incubation induces a dose-responsive increase in cytokine G-CSF in PBMC after in vitro stimulation (figure 14). G-CSF induction is qualitatively and quantitatively similar to the 35624 incubation. Example 7 - Effect of 121A on cytokine production by dendritic cells summary
[0101] The immune response is a strictly regulated process that usually results in protection against infection and tolerance of harmless environmental antigens. However, in inflammatory disease, the activated immune response results in a chronic proinflammatory state characterized by the activation of the innate immune response and expansion of subsets of T cells. Currently, the treatment of inflammatory disease is centered on the suppression of key inflammatory mediators or populations of inflammatory cells. However, these approaches provide only a temporary suppression of the symptoms of the disease. Successful long-term prevention or treatment can only be provided by improving the cellular regulatory processes that protect against pro-inflammatory responses that induce damage. Bifidobacterium AHF121A is a probiotic microbe that selectively stimulates the secretion of IL-10 from the innate immune system (ie, dendritic cells) and induces polarization of Foxp-3 regulatory T cells in vitro. In vivo, IL-10 secretory and regulatory T cells are potent suppressors of aberrant inflammatory responses. Treq cells
[0102] The fundamental role of regulatory T cells (Treg) in maintaining immune tolerance has been demonstrated in a wide range of animal models, in which the adoptive transfer or deliberate expansion of Treg cells has been shown to prevent or cure various T-cell-mediated diseases, including allergy, asthmatic pulmonary inflammation, autoimmune diseases and allograft rejection, by restoring immune tolerance to allergens, self antigens or alloantigens [8]. Multiple molecular mechanisms for Treg-mediated immunosuppression have been described and of particular importance are those with IL-10 secretion [9]. Absence of function or defective function of Treg cells was correlated with hyper IgE syndrome, hypereosinophilia and autoimmunity in humans, while the presence was associated with immunological tolerance [10]. Studies of mechanisms by which responses, immune to non-pathogenic environmental antigens have resulted in allergy or non-harmful immunity have shown that Treg cells producing allergen-specific IL-10 (TR1 cells) are the dominant subset of T cells in healthy individuals [11, 12] . Repeated exposure of healthy non-allergic beekeepers to bee venom antigens during the bee culture season represents a valuable in vivo model for verifying mechanisms of immunological tolerance to venom antigens [13]. After multiple bee stings, TH1 and TH2 cells specific to bee antigens switched to IL-10 secretion TR1 cells. This occurs in parallel with the suppression of late-stage skin responses to allergens and inhibition of TH1 cells and TH2 cells specific to allergens. The response is observed as the exposure to the venom persists and returns to the initial levels in 2 to 3 months after the end of the bee culture season.
[0103] Several strategies, which are designed to improve Treg function in vivo, are currently under investigation. These include the adoptive transfer of inducible or constitutive Treg cells and their induction by specific adjuvants or immunomodulators. These approaches are attractive compared to conventional treatments, since the antigen-specific suppressive capacity of Treg cells does not result in general immunosuppression and can actually lead to long-lasting antigen-specific regulation in vivo. In addition, individual patient-specific treatments are possible with limited side effects. Many immunomodulators that have been developed or are under development, such as rapamycin, the co-stimulation blocker abatacept CD80 / CD86: CD28 (Orencia; Bristol-Myers Squibb), non-mitogenic anti-CD3 monoclonal antibodies, anti-tumor necrosis factor alpha mAbs ((TNF-α) and T cell depletion have direct or indirect effects on Treg cells, which can enhance or suppress their function [14 to 18]. There is a selective advantage of expanding a population of Treg cells that can aim to organ (or the lymph nodes that drain the organ) through recognition of an allergen or an antigen expressed in inflamed organs in mouse models. [19] Thus, the transfer of organ-specific Treg cells can be effective in suppressing continued disease , although these Treg cells do not necessarily need to recognize exactly the same autoantigen as the self-aggressive effector cells. [20] This has implications for therapeutic strategies that aim to targeting the arm of immunological tolerance Treg cells against allergens, autoantigens or transplantation antigens. Possibilities for adoptive transfer of Treg cells or small molecular compounds that induce Treg cells in tissue are being investigated [19], but no double-blind, placebo-controlled study has been conducted so far. To date, allergen-specific immunotherapy (IAE) is the only specific approach to antigens that induces the production and activation of Treg cells in humans. Allergen-specific immunotherapy (IAE) induces Treg cells and TR1-like cells that secrete IL-10 and treatment with glucocorticoid and β2 adrenergic agonists appears to promote the number e. activity of these cells [21 to 23]. The essential transcriptional elements that regulate the expression of the Foxp3 promoter have recently been recorded which will provide new objectives for the development of innovative therapies [24, 25]. Microbes as innovative therapeutic options
[0104] The interest in the administration of microbes or microbial metabolites in the treatment of aberrant inflammatory activity is gaining momentum. Typical microbes currently being examined include Bifidobacteria, Lactobacilli, non-pathogenic E. coli and strains of Bacteroides [26-31]. The protective effects associated with these microbes are probably mediated by multiple mechanisms involving epithelial cells, dendritic cells and T cells. However, a common feature of these microbes, which is being increasingly reported, is the ability to induce Treg cells. For example, encounters with a mixture of commensal microbes (probiotic cocktail VSL # 3) in the murine intestine have been shown to activate the development of mucous Treg cells that is associated with attenuation of inflammation in a murine model of colitis [32]. In addition, the consumption of a Bifidobacterium infantil strain promotes the conversion of Treg cells and protects against NPS-kB activation induced by lipopolysaccharide LPS in vivo while Lactobacillus reuteri induces Treg cells that protect against an allergic pulmonary response in rats [ 33, 34]. Treg cells are derived from the thymus but can also be induced in peripheral organs, including the gastrointestinal mucosa [35, 36]. CD103 + dendritic cells in the mucosa are largely responsible for converting Treg cells via TGF-β and retinoic acid-dependent processes [37, 38]. The conversion is probably triggered by specific gastrointestinal environmental factors associated with the presence of a large number of commensal organisms. However, it is unlikely that all commensal microbes will be equally effective in inducing Treg cells in vivo. A recent study, comparing multiple commensal organisms (Bifidobacterium longum AH1206, Bifidobacterium AH1205 & Lactobacillus salivarius AH102), showed that Bifidobacterium longum AH1206 induced Treg cells and was also able to protect against the recruitment of eosinophils to the lung and lung IgE in murine models [39]. The other bacterial strains did not effectively induce Treg cells and were not able to protect against allergic inflammation in the same models. Therefore, induction of Treg cells can be a critical feature of a healthy microbiota that is a protection against the development of aberrant immune reactivity to potential allergens. In addition to the use of live microbes for the treatment of allergy, another stimulating approach is the identification of microbial factor (s) responsible for the beneficial effect and the isolated use of these isolated factor (s). For example, polysaccharide A (PSA) derived from Bacteroides fragilis promotes an adequate Thl / Th2 balance in a germ-free rat after presentation by dendritic mucous cells and protects against colitis in an animal model via IL-10-secreting CD4 + T cells. [29, 40]. The continued identification of compounds from new microbes that induce activity of tolerogenic dendritic cells and Treg will undoubtedly result in innovative therapeutic molecules for evaluation in clinical studies. Differentiation and maturation of dendritic cells
[0105] Human monocytes were isolated from blood using a combination of Ficoll density gradient centrifugation and cell separation using magnetic microspheres coated with specific CD-14 antibody (MiltentyiBiotec). The purity of the isolated CD14 + cell fraction was greater than 90% in all experiments. To generate immature dendritic cells (DC) (iDCs), the purified CD14 + cells were cultured for 5 days in the presence of IL-4 (R&D systems) and GM-CFS (R&D systems) to differentiate into myeloid dendritic cells. On day 6, the cells were not stimulated (iDCs) or were stimulated with lipopolysaccharide (LPS) (1 mg / mL) 5x105 MDDCs were stimulated with or bacterial cells for 24 hours. B longum strains AHF121A (bacteria: DC ratio of 10: 1 (5x106), bacteria: DC ratio of 1: 1 (5x105) for 24 hours. As anticipated, as a consequence of antibiotic application, no bacterial growth was observed during During this period, the supernatants were isolated and analyzed for IL-10 and IL-12p70 levels using a Luminex multiplex multipex platform. Isolation of human CD4 + T cells and coculture with dendritic cells (DCs)
[0106] PBMCs were isolated by centrifuging buffy coats in Lymphoprep gradients. CD4 + T cells were separated using negative selection affinity columns (R&D systems) according to the manufacturer's instructions. After separation, T cells were washed and resuspended in RPMI 1640 culture medium supplemented with 10% serum. fetal bovine inactivated by heating, 100 IU / mL penicillin, 100 µg / mL streptomycin, and 2 mmol / L L-glutamine. Purified CD4 + T cells (1 x 106 / ml) were stimulated by the combination of immobilized anti-CD3 (1 pg / ml) and soluble anti-CD28 (5 pg / ml) mAbs (Pharmingen). Subsequently, the purified CD4 + T cells were incubated with the above dendritic cells (DCs). After 48 h, CD4 + T cells were permeabilized and stained for CD25 and Foxp-3. The cells were evaluated using flow cytometry.
[0107] The results show that stimulated AHF121A dendritic cells activate the polarization and / or expansion of the subset of regulatory T cells that express CD25 and Foxp-3. Probiotics have a different ability to induce cytokine production by DCs
[0108] The type of cytokine released may have an impact on the polarization of T cells. Therefore, we analyzed the production of IL-12p70, and IL-10 by MoDCs after 24 h of treatment with bacteria, as above. The lipopolysaccharide LPS fox is a powerful inducer of all cytokines tested, while AHF121A caused a differential release of cytokine (figure 15). AHF121A induced lower levels of IL-10 when compared to lipopolysaccharide LPS but did not induce a detectable level of IL-12p70. Thus, AHF121A had a reduced inflammatory potential. The difference in cytokine production reflects a different polarization capacity of T cells.
[0109] The release of cytokine by DCs is important to trigger the polarization of T cells in cells. regulators Thl, Th2, Thl7 or T. Due to the differences observed in cytokine production, we further tested whether monocyte-derived dendritic cells (MDDCs) generated by AHF121A have the potential to induce Foxp3 + T regs. Dendritic cells (DCs) were incubated with AHF121A for 5 days and then co-cultured with highly purified virgin allogeneic CD4 + T cells. The population of Treg CD4 + Foxp3 + was then analyzed by FACS. The results show that stimulated AHF121A dendritic cells activate the polarization and / or expansion of the subset of regulatory T cells that express CD25 and Foxp-3. (figure 16).
[0110] We postulate that AHF121A generated tolerogenic dendritic cells (DCs), which, in turn, induced the generation of CD4 + Foxp3 + Tregs. In fact, we demonstrated that monocyte-derived dendritic cells (MDDCs) cultured with AHF121A can convert CD4 + CD25 T cells into CD4 + CD25-Foxp3 + T cells. In short, AHF121A exerted powerful immunomodulatory effects through upward regulation or potentiation of Treg generation by in vitro MDDCs. You. The results showed evidence of the generation of CD4 + CD25-Foxp3 + Tregs in response to AHF121A in vitro, an effect that may be therapeutically useful for the modulation of inflammatory immune disorders in vivo. (figure 16).
[0111] It has been shown earlier that some probiotics (ie L. casei and reuteri) can induce the development of regulatory T cells (32, 41, 42). Bifidobacterium AH1206 has been shown to mediate the potent activation of regulatory T cells in 3 different animal models. In addition, consumption of Bifidobacterium AH1206 protected against the recruitment of eosinophils into the lung and prevented the induction of IgE serum. It is postulated in this document that regulatory T cells play an important role in the regulation of allergen-specific inflammatory responses (39). Multiple studies in animal models indicate that CD25 CD25 Foxp3 cells are recruited into the lungs and draining lymph nodes and can suppress allergen-induced pulmonary eosinophilia, mucosal hypersecretion and airway hyperresponsiveness (43-48).
[0112] Numerous studies in humans and animals now indicate that irritable bowel syndrome (IBD -inflammatory bowel disease) results from a loss of tolerance to commensal bacteria; the study The Round and Mazmanian (49) shows that polysaccharide A (PSA) directs the development of T regs during the protection and cure of experimental colitis. These findings are consistent with studies showing that the production of IL-10 inducible by Foxp3 + T cells is important for mediating tolerance on mucosal surfaces and preventing intestinal inflammation (49, 50). Example 8 - Example compositions
[0113] The following examples are examples of dry feed compositions comprising the probiotic bifidobacteria of the present invention.
[0114] The following examples are examples of wet pet food compositions comprising the probiotic Bifidobacteria longum of the present invention.
[0115] The following examples are examples of yogurt-based supplement compositions comprising the probiotic Bifidobacteria longum of the present invention.
[0116] Although particular embodiments of the present invention have been illustrated and described, it should be apparent to those skilled in the art that various other changes and modifications can be made without departing from the character and scope of the invention. Therefore, it is intended to cover in the appended claims all such changes and modifications that fall within the scope of the present invention.

权利要求:
Claims (11)
[0001]
Formulation comprising a strain of Bifidobacterium NCIMB 41675, CHARACTERIZED by additionally comprising a probiotic material.
[0002]
Formulation according to claim 1, CHARACTERIZED by the fact that it additionally comprises a prebiotic material.
[0003]
Formulation according to any one of claims 1 to 2, CHARACTERIZED by the fact that it additionally comprises an ingestible vehicle.
[0004]
Formulation according to claim 3, CHARACTERIZED by the fact that the ingestible vehicle is a pharmaceutically acceptable vehicle, such as a capsule, tablet or powder.
[0005]
Formulation according to any one of claims 1 to 2, CHARACTERIZED by the fact that it comprises an ingestible vehicle that can be a food product such as an oil suspension, a milk-based suspension, cheese, a butter-based composition cocoa, a composition based on a sauce and / or yogurt.
[0006]
Food FEATURED for comprising a formulation, as defined in any one of claims 1 to 5.
[0007]
Food, according to claim 6, CHARACTERIZED by the fact that it is a dry food.
[0008]
Food, according to claim 6, CHARACTERIZED by the fact that it is a moist food.
[0009]
Food according to any one of claims 6 to 8, CHARACTERIZED by the fact that it also comprises a probiotic material.
[0010]
Food according to any one of claims 6 to 9, CHARACTERIZED by the fact that it also comprises a prebiotic material.
[0011]
Food according to any one of claims 6 to 10, CHARACTERIZED by the fact that it is a pet food.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112012010923B1|2021-03-23|BIFIDOBACTERIA STRAIN

---

JP4938005B2|2012-05-23|Lactobacillus, a feline probiotic

---

JP4938006B2|2012-05-23|Feline probiotic bifidobacteria

---

BRPI0417826B1|2020-11-03|composition comprising a canine probiotic pseudolongum bifidobacterial strain

---

JP5172151B2|2013-03-27|How to use probiotic bifidobacteria for companion animals

---

JP4607124B2|2011-01-05|Canine probiotic bifidobacteria globosum

---

ES2366542T3|2011-10-21|LACTOBACILLUS PROBIÓTICOS CANINOS.

---

JP5709883B2|2015-04-30|Novel Lactobacillus plantarum and composition containing the same

---

CA2782052C|2018-01-30|Methods of use of probiotic lactobacilli for companion animals

---

US9259019B2|2016-02-16|Bifidobacteriumstrain

---

BRPI0611492B1|2021-10-13|BIFIDOBACTERIA PROBIOTICS FELINE

同族专利:

---

公开号 | 公开日

---

CA2779597C|2018-03-27|

---

EP2823822B1|2016-10-12|

---

AU2010317423B2|2014-07-10|

---

CN103037875A|2013-04-10|

---

BR112012010923A2|2018-03-06|

---

EP2498790A1|2012-09-19|

---

RU2012116029A|2013-12-20|

---

CA2779597A1|2011-05-19|

---

EP2823822A1|2015-01-14|

---

MX2012005449A|2012-09-07|

---

ES2610829T3|2017-05-03|

---

AU2010317423A1|2012-05-31|

---

JP2013509204A|2013-03-14|

---

JP5600179B2|2014-10-01|

---

WO2011058536A1|2011-05-19|

---

PL2823822T3|2017-09-29|

---

CN103037875B|2014-11-05|

---

RU2557310C2|2015-07-20|

---

AU2010317423C1|2015-01-22|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

JPS6234727B2|1979-02-27|1987-07-28|Yakult Honsha Kk|

---

US4781939A|1986-10-28|1988-11-01|Nestec, S.A.|Layered meat emulsion product and method of producing same|

---

DE3933528C1|1989-10-04|1990-12-06|Effem Gmbh, 2810 Verden, De|

---

US5952033A|1996-12-24|1999-09-14|Nestec S.A.|Gelatinized cereal product containing oligosaccharide and processes of preparing and using same|

---

DE69707413T3|1997-01-09|2009-07-02|Société des Produits Nestlé S.A.|Probiotics containing cereal product|

---

US6133323A|1997-04-09|2000-10-17|The Iams Company|Process for enhancing immune response in animals using β-carotene as a dietary supplement|

---

US5932258A|1998-04-06|1999-08-03|The Iams Company|Composition and process for improving glucose metabolism in companion animals|

---

ID29150A|1999-01-15|2001-08-02|Entpr Ireland Cs|USE OF LACTOBACILLUS SALIVARIUS|

---

DK1179984T3|1999-05-27|2005-12-27|Iams Company|Method of Preparation of a Composition for Improving the Immune Defense of Pets Using a Combination of Antioxidants|

---

NZ523010A|2000-05-25|2004-06-25|Nestle Sa|Lactic acid bacteria strains and their use as probotics for pet food|

---

EP1227152A1|2001-01-30|2002-07-31|Société des Produits Nestlé S.A.|Bacterial strain and genome of bifidobacterium|

---

US20040265279A1|2003-05-08|2004-12-30|Timothy Dinan|Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity|

---

US8877178B2|2003-12-19|2014-11-04|The Iams Company|Methods of use of probiotic bifidobacteria for companion animals|

---

ES2381211T3|2006-02-15|2012-05-24|Nestec S.A.|Use of Bifidobacterium longum to prevent and treat inflammations|

---

MX2009010418A|2007-03-28|2010-02-18|Alimentary Health Ltd|Probiotic bifidobacterium strains.|

---

NZ580005A|2007-03-28|2012-03-30|Alimentary Health Ltd|Probiotic bifidobacterium strain 41382|

---

ES2566496T3|2008-11-11|2016-04-13|Alimentary Health Limited|Bifidobacterium longum|AUPQ899700A0|2000-07-25|2000-08-17|Borody, Thomas Julius|Probiotic recolonisation therapy|

---

WO2011151941A1|2010-06-04|2011-12-08|国立大学法人東京大学|Composition having activity of inducing proliferation or accumulation of regulatory t cell|

---

RU2013109251A|2010-08-04|2014-09-10|Томас Джулиус БОРОДИ|COMPOSITIONS FOR TRANSPLANTATION OF FEKAL FLORA AND METHODS FOR THEIR RECEIVING AND APPLICATION AND DEVICES FOR THEIR DELIVERY|

---

EP3569690A1|2011-12-01|2019-11-20|The University of Tokyo|Human-derived bacteria that induce proliferation or accumulation of regulatory t cells|

---

JP6234331B2|2014-06-13|2017-11-22|森永乳業株式会社|Schizophrenia treatment|

---

BR112017024777A2|2015-05-22|2018-08-07|Univ Arizona State|use of a pharmaceutical composition and a non-absorbable antibiotic for treating autistic spectrum disorder cross reference to related applications?|

---

WO2018071537A1|2016-10-11|2018-04-19|Crestovo Holdings Llc|Compositions and methods for treating multiple sclerosis and related disorders|

---

US11213549B2|2016-10-11|2022-01-04|Finch Therapeutics Holdings Llc|Compositions and method for treating primary sclerosing cholangitis and related disorders|

---

CN107334786B|2016-12-29|2018-08-28|哈尔滨学院|Bifidobacteria viable bacteria capsule and its application in preparing prevention premature ovarian failure drug|

---

US11040073B2|2017-04-05|2021-06-22|Finch Therapeutics Holdings Llc|Compositions and methods for treating diverticulitis and related disorders|

---

US11166990B2|2018-07-13|2021-11-09|Finch Therapeutics Holdings Llc|Methods and compositions for treating ulcerative colitis|

---

EP3849574A1|2018-09-10|2021-07-21|Lactobio A/S|Method for reducing the transfer of pathogenic microorganisms|

---

US20220015998A1|2018-12-21|2022-01-20|Lactobio A/S|Topical composition comprising viable microorganisms|

---

EP3906300A1|2019-01-04|2021-11-10|Lactobio A/S|Strains, composition and method of use|

---

AU2020279533A1|2019-05-20|2021-12-23|Lactobio A/S|Composition for treatment, alleviation or prophylaxis of acne|

---

CA3142389A1|2019-06-13|2020-12-17|Lactobio A/S|A gel composition comprising viable microorganisms|

---

WO2021024915A1|2019-08-07|2021-02-11|日清食品ホールディングス株式会社|Bifidobacterium having low activity of inducing generation of inflammatory cytokines and high activity of inducing generation of anti-inflammatory cytokines|

法律状态:
2018-04-24| B25A| Requested transfer of rights approved|Owner name: ALIMENTARY HEALTH LIMITED (US) , MARS, INCORPORATE |

---

2018-06-26| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|

---

2019-01-08| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-09-17| B07G| Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]|

---

2019-11-12| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-05-12| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]|

---

2020-12-01| B07A| Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]|

---

2021-02-09| B09A| Decision: intention to grant|

---

2021-03-23| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US12/616,752|US9771624B2|2008-11-11|2009-11-11|Bifidobacterium longum|

---

US12/616,752|2009-11-11|

---

IE2010/0290|2010-05-11|

---

IE20100290|2010-05-11|

---

PCT/IE2010/000067|WO2011058536A1|2009-11-11|2010-11-11|A bifidobacterium strain|

---